Bai Ping, Lu Xiaoxia, Liu Yan, Lan Yu, Wang Hao, Fiedler Stephanie, Striar Robin, Wang Changning
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, United States.
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, P.R. China.
ACS Med Chem Lett. 2021 Jan 8;12(2):282-287. doi: 10.1021/acsmedchemlett.0c00650. eCollection 2021 Feb 11.
In this paper, we report the design, synthesis, and biological evaluation of the first selective bromodomain and extra-terminal domain (BET) BD1 bromodomains of the PET radiotracer [F]PB006. The standard compound PB006 showed high affinity and good selectivity toward BRD4 BD1 ( = 100 nM and 29-fold selectively for BD1 over BD2) in an binding assay. PET imaging experiments in rodents were performed to evaluate the bioactivity of [F]PB006 . A biodistribution study of [F]PB006 in mice revealed high radiotracer uptake in peripheral tissues, such as liver and kidney, and moderate radiotracer uptake in the brain. Further blocking studies demonstrated the significant radioactivity decreasing (20-30% reduction compared with baseline) by pretreating unlabeled PB006 and JQ1, suggesting the high binding selectivity and specificity of [F]PB006. Our study indicated that [F]PB006 is a potent PET probe selectively targeting BET BD1, and further structural optimization of the radiotracer is still required to improve brain uptake to support neuroepigenetic imaging.
在本文中,我们报告了正电子发射断层显像(PET)放射性示踪剂[F]PB006首个选择性溴结构域和额外末端结构域(BET)BD1溴结构域的设计、合成及生物学评价。在放射性配体结合试验中,标准化合物PB006对BRD4 BD1表现出高亲和力和良好的选择性(解离常数 = 100 nM,对BD1的选择性是BD2的29倍)。进行了啮齿动物的PET成像实验以评估[F]PB006的生物活性。[F]PB006在小鼠体内的生物分布研究显示,放射性示踪剂在肝脏和肾脏等外周组织中摄取较高,而在大脑中的摄取适中。进一步的阻断研究表明,通过用未标记的PB006和JQ1预处理,放射性显著降低(与基线相比降低20 - 30%),这表明[F]PB006具有高结合选择性和特异性。我们的研究表明,[F]PB006是一种选择性靶向BET BD1的有效PET探针,仍需要对该放射性示踪剂进行进一步的结构优化以提高大脑摄取,从而支持神经表观遗传学成像。